Neurocrine Biosciences, Inc. (NBIX) has increased INGREZZA 2024 net product sales guidance to $2.25 - $2.3 billion. Non-GAAP R&D expense is now expected in a range of $600 million to $630 million.
Kevin Gorman, CEO of Neurocrine Biosciences, said: "We are in the process of building our endocrinology team and expanding the INGREZZA salesforce, positioning our company for continued strong growth in the years ahead."
Second quarter earnings came in at $65.0 million, or $0.63 per share compared with $95.5 million, or $0.95 per share, in last year's second quarter. Adjusted earnings per share was $1.63 compared to $1.25. Analysts on average had expected the company to earn $1.03 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.
The company's revenue for the quarter rose 30.4% to $590.2 million from $452.7 million last year. INGREZZA net product sales were $580 million, grew 32% compared to the second quarter 2023.
Shares of Neurocrine Biosciences are up 4% in pre-market trade on Thursday.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.